Clinical Edge Journal Scan

Robotic-assisted distal gastrectomy: A feasible treatment option for advanced gastric cancer


 

Key clinical point: Compared with laparoscopic-assisted distal gastrectomy (LADG), robotic-assisted distal gastrectomy (RADG) results in less operative blood loss, more retrieved lymph nodes (LN), and similar complication rates and oncological outcomes in advanced gastric cancer.

Major finding: Patients who underwent RADG vs LADG had lower operative blood loss (139.3 ± 97.8 vs 167.3 ± 134.2 mL; P < .001); higher retrieved LN number (31.4 ± 12.1 vs 29.4 ± 12.3; P = .015); and similar overall complication rate (13.7% vs 16.6%; P = .242), 3-year overall survival rate (75.5% vs 73.1%; P = .471), and 3-year disease-free survival rate (72.9% vs 71.4%; P = .763).

Study details: Findings are from a retrospective study that propensity score-matched patients with advanced gastric cancer who underwent RADG (n = 410) with those who underwent LADG (n = 410).

Disclosures: This study was sponsored by the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Gao G et al. Surgical and oncological outcomes of robotic- versus laparoscopic-assisted distal gastrectomy with D2 lymphadenectomy for advanced gastric cancer: A propensity score-matched analysis of 1164 patients. World J Surg Oncol. 2022;20:315 (Sep 28). Doi: 10.1186/s12957-022-02778-w

Recommended Reading

Special CRC prevention efforts may focus on population with higher serum uric acid levels
MDedge Hematology and Oncology
Preoperative vitamin D levels may influence outcomes in patients with localized CRC undergoing resection
MDedge Hematology and Oncology
Liver-dominant mCRC: Prognostic factors for efficacy outcomes after TARE
MDedge Hematology and Oncology
Emergency readmission frequent after curative intent CRC surgery
MDedge Hematology and Oncology
Longer interval between bevacizumab exposure and CRC surgery could prevent additional mortality risk
MDedge Hematology and Oncology
FDA approves new immunotherapy combo for liver cancer
MDedge Hematology and Oncology
Pancreatic cancer screening appears safe, effective for high-risk patients
MDedge Hematology and Oncology
EUS-guided RF ablation doubles survival for unresectable pancreatic cancer
MDedge Hematology and Oncology
Some young CRC patients are missing out on genetic counseling, testing
MDedge Hematology and Oncology
Paclitaxel + carboplatin + capecitabine regimen shows promise in advanced gastric cancer
MDedge Hematology and Oncology